Actavis Pharma Limited (Now Allergan) company information, Employees & Contact Information

Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers PR Newswire

Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training La Grande Observer

Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency PR Newswire

Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World AbbVie News Center

Allergan Announces Commencement of Mailing of Proxy Statement AbbVie News Center

Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign PR Newswire

Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025 PR Newswire

Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD) PR Newswire

Allergan Receives FDA Clearance For CoolTone™ Device PR Newswire

AbbVie Inc. Completes Acquisition of Allergan plc PR Newswire

Allergan Expands REFRESH® Portfolio With New REFRESH® RELIEVA™ Lubricant Eye Drop Product Line PR Newswire

Announcement relating to the voluntary delisting of Allergan Notes PR Newswire

Allergan Suspends Sales and Withdraws Supply of Textured Breast Implants in European Markets PR Newswire

Allergan Successfully Completes Vitae Tender Offer PR Newswire

Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders PR Newswire

Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD) PR Newswire

Allergan Receives U.S. FDA Approval for UBRELVY™ for the Acute Treatment of Migraine with or without Aura in Adults PR Newswire

Allergan Teams Up With Media Mogul Wendy Williams to Debut the Patient Empowerment Campaign - Toilet Talk PR Newswire

Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH PR Newswire

Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction AbbVie News Center

U.S. FDA Accepts Allergan's New Drug Application for Bimatoprost Sustained-Release in Patients with Open-Angle Glaucoma or Ocular Hypertension PR Newswire

Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals PR Newswire

Allergan Unveils Spotlyte™, A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments PR Newswire

Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101 PR Newswire

Allergan to Host Medical Aesthetics Day Event on September 14, 2018 PR Newswire

Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension PR Newswire

Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign PR Newswire

Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne PR Newswire

Allergan Announces Changes to Board Leadership PR Newswire

Actavis plc is now Allergan plc PR Newswire

Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering PR Newswire

Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial PR Newswire

Allergan® Announces First Annual National BOTOX® Cosmetic (onabotulinumtoxinA) Day PR Newswire

Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines PR Newswire

Allergan Announces Availability of RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle PR Newswire

Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients PR Newswire

Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to Alzheimer's Disease PR Newswire

Allergan to Acquire Keller Medical, Inc., Adding Keller Funnel® to Company's Leading Plastic Surgery Portfolio PR Newswire

Allergan Announces Pricing of Public Offering of Senior Notes to Refinance Existing Debt PR Newswire

Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting® PR Newswire

Allergan Announces Resolution Concluding Federal Investigation Into Warner Chilcott Sales And Marketing Practices PR Newswire

Allergan Receives FDA Clearance for the XEN® Gel Stent, a New Surgical Treatment for Refractory Glaucoma PR Newswire

Allergan Announces Submission of Prior Approval Supplement for RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Multi-Dose Preservative-Free Bottle PR Newswire

Allergan Announces FDA Approval of NATRELLE INSPIRA® SoftTouch Breast Implants PR Newswire

Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD) PR Newswire

Allergan Files Suits Against Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC PR Newswire

Allergan Successfully Completes LifeCell Acquisition PR Newswire

Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline PR Newswire

Allergan Successfully Completes ZELTIQ® Aesthetics Acquisition PR Newswire

Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program PR Newswire

Allergan Successfully Completes Naurex Acquisition PR Newswire

Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment PR Newswire

Allergan Acquires Medical Dermatology and Aesthetic Medicine Company Anterios to Expand Neurotoxin Pipeline PR Newswire

New Study Showcases Economic Impact of Allergan's Operations on New Jersey Economy PR Newswire

Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions PR Newswire

Allergan Successfully Completes AqueSys Acquisition, Adding XEN45 Minimally Invasive Implantable Shunt for Glaucoma PR Newswire

Allergan Announces Sale of Anda Distribution Business to Teva Pharmaceuticals PR Newswire

Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System to Best-in-Class Medical Aesthetics Portfolio PR Newswire

Allergan Announces Collaboration with AstraZeneca to Develop and Commercialize ATM-AVI (aztreonam and avibactam) for Antibiotic-Resistant Gram-Negative Infections PR Newswire

Allergan Launches Generic Version of INVEGA® (paliperidone) PR Newswire

Allergan plc Completes Divestiture of Global Generics Business to Teva Pharmaceuticals PR Newswire

Ashley Tisdale Joins The Allergan 'Women Who Know' Campaign AbbVie News Center

Allergan Kicks off REFRESH AMERICA Program to Supply First Responders With Free Eye Drops PR Newswire

Allergan Expands Dry Eye Portfolio With Launch Of REFRESH OPTIVE® Gel Drops PR Newswire

Allergan and Richter Provide Update on Cariprazine Program PR Newswire

Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds PR Newswire

FDA Approves BOTOX® Cosmetic (OnabotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines Associated with Frontalis Muscle Activity In Adults PR Newswire

Allergan's BOTOX Vista® (botulinum toxin type A) Receives National Marketing Authorisation in Japan for Treatment of Crow's Feet Lines in Adult Patients PR Newswire

Allergan to Acquire ZELTIQ, Best-in-Class Company in Fast-Growing Body Contouring Segment, for $2.47 Billion PR Newswire

Allergan Acquires Topical Dermatology Company Topokine Therapeutics Adding Non-Invasive Fat Reduction Development Program PR Newswire

Allergan Confirms Generic Abraxane® Patent Challenge PR Newswire

Allergan and Gedeon Richter Plc. Receive FDA Approval of VRAYLAR™ (cariprazine) for Treatment of Manic or Mixed Episodes of Bipolar I Disorder and Schizophrenia in Adults PR Newswire

Allergan and Rugen Therapeutics Announce Collaboration to Discover and Develop Ground-Breaking Medicines to Treat Autism Spectrum Disorders and Obsessive-Compulsive Disorders PR Newswire

Allergan to Acquire Oculeve Dry Eye Disease Development Programs PR Newswire

Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company's Innovative Eye Care Pipeline PR Newswire

Allergan Receives Complete Response Letter from FDA for Prior Approval Supplement for RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Multi-Dose Preservative-Free Bottle PR Newswire

Allergan Receives FDA Approval and Launches First Generic Version of CRESTOR® (rosuvastatin) PR Newswire

Allergan Introduces REFRESH OPTIVE® MEGA-3 Enhanced with Flaxseed Oil, Latest Innovation in the REFRESH® Portfolio PR Newswire

Allergan to Acquire Naurex PR Newswire

Allergan Announces FDA Approval Of RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For The Topical Treatment Of Persistent Facial Erythema Associated With Rosacea In Adults PR Newswire

Allergan Announces FDA Approval of ACZONE® (dapsone) Gel, 7.5% for Treatment of Acne Vulgaris PR Newswire

Allergan Announces FDA Approval of BYVALSON™ (nebivolol and valsartan) PR Newswire

Allergan Confirms Generic Tyvaso® Patent Challenge PR Newswire

Allergan to Acquire KYTHERA Biopharmaceuticals GlobeNewswire

Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults PR Newswire

Allergan Announces U.S. Availability of VRAYLAR™ (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults PR Newswire

Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue MultiVu

AWARD WINNING ACTOR AND HIP-HOP ARTIST COMMON JOINS ALLERGAN’S SEE AMERICA MultiVu

Allergan Breaks Ground on $200 Million Waco Facility Expansion MultiVu

Ozurdex approved for treatment of macular edema Medical Professionals Reference

New Survey Reveals What Women in the U.S. Really Want to Know About BOTOX® Cosmetic (onabotulinumtoxinA) MultiVu

Acuvail approved for post-cataract surgery pain and inflammation Medical Professionals Reference

Allergan launches Juvéderm® VOLUX - the latest evolution in facial filler treatments for those seeking a more defined chin and jawline PR Newswire UK

VIBERZI™ Now Approved in Canada for patients with irritable bowel syndrome with diarrhea (IBS-D) PR Newswire Canada